Skip to main content
. 2008 Oct 1;46(11):3746–3751. doi: 10.1128/JCM.00612-08

FIG. 2.

FIG. 2.

Changes in the anti-F recombinant protein antibodies, anti-F99 synthetic peptide antibodies, and anticore antibodies before and after antiviral therapy in 72 HCV patients. (a) Comparison of the anti-F recombinant protein antibodies before and 6 months after treatment in responders (IFN-R) (a1) (n = 55, P = 0.0002) and nonresponders (IFN-NR) (a2) (n = 17, P = 0.015). (a3) Change in anti-F recombinant protein antibody levels between responders and nonresponders (P = 0.041). (b) Comparison of the anti-F99 synthetic peptide antibodies before and after interferon treatment in responders (b1) (n = 55, P = 0.009) and nonresponders (b2) (n = 17, P = 0.674). (b3) Change in anti-F99 synthetic peptide antibody levels between responders and nonresponders (P = 0.042). (c) Comparison of the anticore antibodies before and after interferon treatment in responders (c1) (n = 55, P = 0.005) and nonresponders (c2) (n = 17, P = 0.471). (c3) Change in anticore antibody levels between responders and nonresponders (P = 0.381). All comparisons were performed by using the t test. In panels a3, b3, and c3, each dot indicates the variation of antibody titers in 6 months after treatment (S/co [OD value]) minus the titer before treatment in each patient.